Entry-competent-replication-abortive African horse sickness virus strains elicit robust immunity in ponies against all serotypes. Issue 23 (27th May 2021)

• Record Type: Journal Article
• Authors: Sullivan, Edward; Lecollinet, Sylvie; Kerviel, Adeline; Hue, Erika; Pronost, Stéphane; Beck, Cécile; Dumarest, Marine; Zientara, Stephan; Roy, Polly
• Is Part Of: Vaccine. Volume 39:Issue 23(2021)
• Page Start: 3161
• Page End: 3168
• Publication Date: 2021-05-27
• Subjects: African horse sickness virus -- Entry competent replication abortive -- Neutralising antibody -- Vaccine; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2021.04.034
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: A cocktail of 9 ECRA-AHSV strains elicits an antibody response to all 9 serotypes. ECRA-AHSV monovalent vaccination induces sustained immunity. ECRA-AHSV strains trigger balanced Th1 and Th2 responses. Abstract: African horse sickness virus (AHSV) is an Orbivirus within the Reoviridae family, spread by Culicoides species of midges, which infects equids with high mortality, particularly in horses and has a considerable impact on the equine industry. In order to control the disease, we previously described Entry Competent Replication Abortive (ECRA) virus strains for each of the nine distinct AHSV serotypes and demonstrated their potential as vaccines, first in type I interferon receptor (IFNAR-/-) knockout mice, and then in ponies. In this report we have investigated whether or not a combination ECRA vaccine comprising nine vaccine strains as two different cocktails is as efficient in ponies and the duration of the immunity triggered by ECRA vaccines. In one study, a group of ponies were vaccinated with a cocktail of 4 vaccine strains, followed by a vaccination of the remaining 5 vaccine strains, mimicking the current live attenuated vaccine regimen. In the second study, ponies were vaccinated with a single ECRA-AHSV strain and monitored for 6 months. The first group of ponies developed neutralising antibody responses against all 9 serotypes, indicating that no cross-serotype interference occurred, while the second group developed robust neutralising antibody responses against the single serotype that were sustained at the same level throughout a 6-month study. The results support our previous data and further validate ECRA vaccines as a safe and efficacious replacement of current live vaccines.